Anti-IL-13 monoclonal antibody
Lebrikizumab
Brand names: Ebglyss
Adult dose
Dose: Loading 500mg SC week 0 and 2; then 250mg SC every 2 weeks until week 16; then 250mg SC every 4 weeks
Route: SC
Frequency: q2-4w
Clinical pearls
- Moderate-severe atopic dermatitis (≥12y) inadequately controlled by topicals
- Specialist dermatology
Contraindications
- Hypersensitivity
Side effects
- Conjunctivitis (very common — class effect)
- Injection site reactions
- Hypersensitivity
Interactions
- Live vaccines
Monitoring
- EASI/IGA
- Conjunctivitis
Reference: BNF; NICE TA970; SmPC; https://bnf.nice.org.uk/drugs/lebrikizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD